CTXR: Citius Pharmaceuticals, Inc. Stock

by  •  • Comments Off on CTXR: Citius Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 31.89
Enterprise Value ($M) 14.58
Book Value ($M) 86.28
Book Value / Share 0.45
Price / Book 0.37
NCAV ($M) 17.20
NCAV / Share 0.09
Price / NCAV 1.85

Profitability (mra)
Return on Invested Capital (ROIC) -0.44
Return on Assets (ROA) -0.37
Return on Equity (ROE) -0.42

Liquidity (mrq)
Quick Ratio 6.75
Current Ratio 6.75

Balance Sheet (mrq) ($M)
Current Assets 28.01
Assets 97.09
Liabilities 10.81
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-08 13G/A BlackRock, Inc. 4.80 1.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT P
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT
2024-02-14 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO
2023-12-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 4,986,081 14,993,449 33.26
2024-11-21 1,047,028 4,246,213 24.66
2024-11-20 1,049,194 4,123,869 25.44
2024-11-19 1,167,050 3,748,366 31.13

(click for more detail)

Similar Companies
CRVO – CervoMed Inc. CSBR – Champions Oncology, Inc.
CSCI – COSCIENS Biopharma Inc. CUE – Cue Biopharma, Inc.
CVKD – Cadrenal Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io